Skip to main content

Table 2 Activated P38 is associated with luminal phenotype (ER &/or PR expression) and favourable clinicopathological prognostic indicators (N = 1332)

From: Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair

Variable pan-P38 nuclear p-P38
Negative/low Positive/high p Negative/low Positive/high p
Age < 50 yrs 187 57.9% 136 42.1% 0.258 318 70.0% 136 30.0% 0.751
≥50 yrs 363 61.7% 225 38.3% 620 70.9% 254 29.1%
Size < 20 mm 232 56.2% 181 43.8% 0.025 * 421 65.2% 225 34.8% < 0.001 *
≥20 mm 316 63.7% 180 36.3% 516 75.8% 165 24.2%
Stage 1 334 60.5% 218 39.5% 0.890 550 67.9% 260 32.1% 0.007 *
2–3 214 59.9% 143 40.1% 387 74.9% 130 25.1%
Grade 1–2 237 55.4% 191 44.6% 0.004 * 413 62.5% 248 37.5% < 0.001 *
3 311 64.7% 170 35.3% 524 78.7% 142 21.3%
NPI good / medium 440 58.9% 307 41.1% 0.095 760 68.8% 344 31.2% 0.002 *
Poor 109 66.1% 56 33.9% 179 79.2% 47 20.8%
VI negative or suspected 354 59.9% 237 40.1% 0.722 602 67.9% 284 32.1% 0.002 *
positive (definite) 192 61.1% 122 38.9% 331 76.1% 104 23.9%
ER Negative 167 74.6% 57 25.4% < 0.001 * 244 77.7% 70 22.3% < 0.001 *
Positive 379 55.3% 306 44.7% 690 68.7% 315 31.3%
PR Negative 265 72.4% 101 27.6% < 0.001 * 398 76.5% 122 23.5% < 0.001 *
Positive 264 51.4% 250 48.6% 507 67.3% 246 32.7%
HER2 Negative 463 60.5% 302 39.5% 1.000 775 70.3% 327 29.7% 0.237
Positive 66 61.1% 42 38.9% 127 75.1% 42 24.9%
  1. NPI Nottingham Prognostic Index, VI vascular invasion
  2. *p value in bold type indicates statistical significance defined as p < 0.05 by Χ2 test